Last updated: September 24, 2026
Rituximab and hyaluronidase human, marketed in the United States as Rituxan Hycela by Genentech, is a subcutaneous formulation of rituximab enabled by recombinant human hyaluronidase PH20. Its commercial value comes from administration efficiency, not a new anti-CD20 mechanism. The product competes with intravenous rituximab biosimilars, including Truxima, Ruxience, and Riabni, while retaining a differentiated position in infusion-center workflow.
Rituxan Hycela was approved by the FDA on June 21, 2017. It is used in certain adult patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia after an initial full intravenous dose of rituximab has been tolerated.[1] Roche does not publicly report Rituxan Hycela revenue separately from the broader Rituxan/MabThera franchise. The financial trajectory is therefore best assessed through total rituximab sales, product-channel mix, biosimilar erosion, and the value of reduced administration time.
What is rituximab and hyaluronidase human?
Rituximab and hyaluronidase human combines the anti-CD20 antibody rituximab with recombinant human hyaluronidase PH20. Hyaluronidase temporarily modifies the extracellular matrix in subcutaneous tissue, allowing administration of a large-volume antibody dose under the skin.
The product is supplied in two fixed-dose presentations:
| Presentation |
Rituximab dose |
Hyaluronidase dose |
Administration |
| Rituxan Hycela 1,400 mg/23,400 units |
1,400 mg |
23,400 units |
Subcutaneous |
| Rituxan Hycela 1,600 mg/26,800 units |
1,600 mg |
26,800 units |
Subcutaneous |
The labeled administration time is approximately five to seven minutes, compared with substantially longer intravenous rituximab infusions. The product is not intended to replace the first rituximab dose in patients who have not previously received rituximab.[1]
What indications does Rituxan Hycela have?
FDA-approved indications include:
- Previously untreated follicular lymphoma, in combination with chemotherapy, followed by maintenance treatment in responders.
- Relapsed or refractory follicular lymphoma.
- Previously untreated diffuse large B-cell lymphoma, in combination with chemotherapy.
- Previously untreated chronic lymphocytic leukemia, in combination with fludarabine and cyclophosphamide.
The product carries administration restrictions because severe and potentially fatal infusion-related reactions, including anaphylaxis, can occur. It is administered only after a patient has received at least one complete intravenous rituximab dose without severe adverse reactions.[1]
How does Rituxan Hycela compare with intravenous rituximab and biosimilars?
The principal commercial distinction is route and administration time rather than clinical mechanism.
| Product category |
Examples |
Route |
Primary commercial advantage |
Main limitation |
| Original intravenous rituximab |
Rituxan, MabThera |
IV |
Established clinical use |
Long infusion-chair time |
| Rituximab biosimilars |
Truxima, Ruxience, Riabni |
IV |
Lower acquisition cost |
No equivalent subcutaneous presentation in the U.S. market |
| Rituximab plus hyaluronidase |
Rituxan Hycela |
SC |
Rapid administration and lower chair use |
Higher formulation complexity and limited interchangeability |
| Other anti-CD20 biologics |
Gazyva, Arzerra and others |
IV or other routes |
Alternative clinical profiles |
Different indications and treatment economics |
The key competitive point is that U.S. rituximab biosimilars have primarily challenged the intravenous franchise. They do not automatically substitute for Rituxan Hycela because the subcutaneous product has a distinct formulation, administration method, labeling, and regulatory pathway.
A provider may still favor an IV biosimilar when drug acquisition cost is the dominant consideration. Rituxan Hycela becomes more attractive when infusion-center capacity, nursing time, patient throughput, and scheduling constraints have high economic value.
What is the FDA regulatory and Orange Book status of Rituxan Hycela?
Rituxan Hycela is a biologic licensed under the Public Health Service Act. It is not regulated as a conventional small-molecule drug under an NDA. The relevant FDA reference source is the Purple Book, not the Orange Book.[2]
The key regulatory dates are:
| Event |
Date |
| U.S. approval of intravenous Rituxan |
November 26, 1997 |
| U.S. approval of Rituxan Hycela |
June 21, 2017 |
| U.S. biosimilar approval of Truxima |
November 28, 2018 |
| U.S. biosimilar approval of Ruxience |
July 23, 2019 |
| U.S. biosimilar approval of Riabni |
December 17, 2020 |
The 12-year reference-product exclusivity framework for biologics is more difficult to apply commercially to Rituxan Hycela than to a new antibody. Rituximab was first licensed in 1997, while the combination product was approved in 2017. Biosimilar applicants generally target the reference rituximab product rather than relying on automatic substitution to the hyaluronidase combination.[1,3]
What patents protect rituximab and hyaluronidase human?
Protection for Rituxan Hycela is based on a combination of formulation, delivery, dosing, and manufacturing rights rather than the original rituximab molecule alone.
Formulation and delivery patents
The relevant patent categories include:
- Compositions containing rituximab and recombinant human hyaluronidase.
- Subcutaneous delivery of high-concentration antibody doses.
- Fixed-dose administration of rituximab with hyaluronidase.
- Treatment methods requiring prior intravenous rituximab exposure.
- Pharmaceutical formulations and stability characteristics.
- Manufacturing and fill-finish processes for large-volume biologic combination products.
The original rituximab composition-of-matter estate is no longer the principal barrier to competition. The commercial protection question is whether combination patents can delay a competing subcutaneous product or increase the cost of designing around the delivery system.
Genentech’s rights are also linked to Halozyme’s Enhanze technology, which uses recombinant human hyaluronidase PH20. Roche and Halozyme entered into a collaboration covering the development and commercialization of subcutaneous biologics using the technology.[4]
How strong is the patent estate?
The estate is stronger against a direct subcutaneous rituximab-hyaluronidase copy than against IV rituximab competition. Its practical strength has four components:
- Rituximab molecule patents have largely expired.
- Biosimilar competition has been established for the IV product.
- The combination product depends on a distinct delivery technology.
- A direct competitor may require separate clinical, formulation, manufacturing, and device work.
The estate is therefore commercially meaningful but not equivalent to the protection of a new molecular entity. A competitor could attack the product through an alternate subcutaneous formulation, a different permeation technology, or an IV biosimilar with lower pricing.
When does Rituxan Hycela lose exclusivity?
There is no single commercial loss-of-exclusivity date comparable to the expiry of a small-molecule composition patent. The product’s effective exclusivity depends on several dates:
| Protection layer |
Commercial effect |
| Rituximab molecule patents |
No longer the main barrier to U.S. competition |
| Biologic regulatory exclusivity |
Tied to reference-product status and FDA pathway |
| Combination patents |
May extend protection for specific subcutaneous compositions or methods |
| Halozyme technology rights |
Can affect access to the enabling delivery platform |
| Clinical and manufacturing know-how |
Raises development cost but does not create statutory exclusivity |
| Provider workflow preference |
Can preserve share after legal exclusivity weakens |
A direct subcutaneous biosimilar would face a more complex development program than an IV rituximab biosimilar. The applicant would need to address the antibody, the hyaluronidase component, the combination formulation, delivery characteristics, immunogenicity, and administration process.
Which companies are challenging the rituximab franchise?
The primary challengers are biosimilar manufacturers targeting IV rituximab:
| Company |
Product |
U.S. status |
| Celltrion Healthcare |
Truxima |
FDA-approved biosimilar |
| Pfizer |
Ruxience |
FDA-approved biosimilar |
| Biogen and Samsung Bioepis |
Riabni |
FDA-approved biosimilar |
| Sandoz |
Rituximab biosimilar programs in selected markets |
International competition |
| Amgen and other major biosimilar developers |
Potential competitive pressure |
Depends on market and regulatory status |
The most important U.S. competitors are Celltrion, Pfizer, and Biogen/Samsung Bioepis. Their products pressure Rituxan franchise pricing even when they do not directly replace Rituxan Hycela.
No major U.S. market has developed around an interchangeable subcutaneous rituximab biosimilar equivalent to Rituxan Hycela. The absence of a direct SC substitute has supported continued differentiation.
What patent litigation affects Rituxan Hycela?
The principal litigation risk is not a broad patent fight over rituximab itself. It is the potential for patent disputes involving:
- Subcutaneous rituximab compositions.
- Hyaluronidase-enabled delivery methods.
- Combination dosing regimens.
- Patent-listing and notice requirements for biosimilar applicants.
- Licensing rights to recombinant hyaluronidase technology.
Publicly disclosed U.S. litigation has focused more heavily on IV rituximab biosimilars and biologic patent procedures than on a successful direct launch of a competing rituximab-hyaluronidase product. The lack of a direct SC biosimilar launch has limited immediate litigation pressure on Rituxan Hycela.
What is the financial trajectory for rituximab?
Rituxan Hycela revenue is not separately disclosed in Roche’s principal financial reporting. Roche reports Rituxan and MabThera at franchise level, combining products and geographic markets.
Representative reported Roche sales were:
| Year |
Rituxan/MabThera sales |
Direction |
| 2021 |
Approximately CHF 2.1 billion |
Declining |
| 2022 |
Approximately CHF 1.7 billion |
Declining |
| 2023 |
Approximately CHF 1.4 billion |
Declining |
Sources report the totals in Swiss francs and may present regional or product definitions differently across annual reports.[5-7]
The decline reflects:
- U.S. and European biosimilar adoption.
- Price concessions and payer pressure.
- Reduced use of the originator IV formulation.
- Mature treatment markets.
- Competition from other CD20-directed therapies.
- The absence of separately reported growth sufficient to offset IV erosion.
Rituxan Hycela can improve the value of remaining originator volume, but it is unlikely to reverse the franchise decline by itself. Its financial role is defensive: preserving selected patients and sites of care, protecting administration economics, and differentiating the originator from IV biosimilars.
What is the revenue exposure?
The overall rituximab franchise remains material but is no longer a major growth engine for Roche. The product is strategically important in hematology, yet its revenue exposure is smaller than Roche’s newer growth products, including Ocrevus, Hemlibra, and Vabysmo.
Because Rituxan Hycela is not reported separately, investors cannot directly calculate its margin, volume, or contribution from public Roche disclosures. The commercial indicators that matter most are:
- Share of rituximab administrations using the SC formulation.
- Net price versus IV biosimilars.
- Hospital and oncology-practice adoption.
- Reimbursement treatment.
- Use in high-throughput infusion centers.
- Expansion or contraction of labeled indications.
- Development of competing SC anti-CD20 products.
What generic or biosimilar launch risks exist?
The near-term risk is continued IV biosimilar substitution, not conventional generic entry. Biologics do not face small-molecule generic substitution under the same pathway.
IV biosimilar risk
IV biosimilars can reduce the benchmark price for rituximab and pressure hospitals to use lower-cost products. This affects Rituxan Hycela indirectly through:
- Lower treatment budgets.
- Increased scrutiny of originator acquisition costs.
- Hospital formulary restrictions.
- Greater use of biosimilar loading doses before maintenance therapy.
- Reduced willingness to pay for the SC convenience premium.
Direct SC biosimilar risk
A direct SC biosimilar would pose a greater threat, but development is more complex. The competitor would need to demonstrate similarity for a product containing both rituximab and hyaluronidase and address delivery-specific risks. The competitive risk is therefore longer-dated than the IV biosimilar threat.
How does Rituxan Hycela compare with competing anti-CD20 drugs?
| Product |
Company |
Route |
Competitive position |
| Rituxan Hycela |
Genentech/Roche |
SC |
Faster administration for selected rituximab patients |
| Rituxan/Rituximab biosimilars |
Multiple companies |
IV |
Lower price and broad clinical familiarity |
| Gazyva/obinutuzumab |
Roche |
IV |
Differentiated antibody and disease-specific positioning |
| Kesimpta/ofatumumab |
Novartis |
SC |
Self-administered option in multiple sclerosis |
| Lunsumio/mosunetuzumab |
Roche |
IV/SC regimen-dependent |
T-cell engaging therapy for selected lymphoma settings |
Rituxan Hycela competes most directly on site-of-care economics. It does not compete solely on efficacy because its active antibody is rituximab, an established therapy with numerous lower-cost IV alternatives.
What is the outlook for Rituxan Hycela?
The expected trajectory is gradual erosion rather than abrupt displacement. The product should retain use where infusion capacity, patient convenience, and established clinical protocols justify the originator premium. Its position is weaker in price-sensitive hospitals and systems with aggressive biosimilar mandates.
The main upside is broader conversion from IV rituximab to SC administration within existing Genentech accounts. The main downside is that hospitals may capture the administration savings while demanding a price close to IV biosimilar benchmarks.
Rituxan Hycela is best viewed as a lifecycle-management product. Its strategic value is higher than its separately disclosed revenue because it protects the originator franchise from becoming a pure commodity. Its financial ceiling remains limited by the mature rituximab market and the availability of low-cost IV biosimilars.
Key takeaways
- Rituxan Hycela was FDA-approved in 2017 for selected lymphoma and leukemia indications.
- Its main commercial advantage is five- to seven-minute subcutaneous administration after an initial IV dose.
- U.S. competition currently comes mainly from IV rituximab biosimilars: Truxima, Ruxience, and Riabni.
- Orange Book listing is not the central framework because Rituxan Hycela is a biologic; the Purple Book and biologic patent procedures are more relevant.
- The remaining patent value is concentrated in combination formulation, hyaluronidase-enabled delivery, dosing, and manufacturing rights.
- Roche’s Rituxan/MabThera revenue declined from roughly CHF 2.1 billion in 2021 to roughly CHF 1.4 billion in 2023.
- Roche does not separately disclose Rituxan Hycela revenue.
- The product faces indirect pricing pressure from IV biosimilars and longer-term risk from a direct subcutaneous competitor.
- Its financial role is defensive lifecycle management rather than franchise growth.
Frequently asked questions
Is Rituxan Hycela interchangeable with rituximab biosimilars?
No. IV rituximab biosimilars are not automatically interchangeable with the subcutaneous rituximab-hyaluronidase combination.
Does Rituxan Hycela contain a new active antibody?
No. It contains rituximab, the same anti-CD20 antibody used in Rituxan, combined with recombinant human hyaluronidase PH20.
Can Rituxan Hycela be given as the first rituximab dose?
Generally no. The label requires an initial full intravenous rituximab dose before subcutaneous administration in appropriate patients.[1]
Why has Rituxan Hycela not eliminated IV rituximab?
Hospitals continue to weigh drug acquisition cost, biosimilar discounts, reimbursement, protocol requirements, and the value of reduced infusion time.
Is there an FDA-approved subcutaneous rituximab biosimilar?
The principal FDA-approved rituximab biosimilars have been IV products. A direct FDA-approved subcutaneous rituximab-hyaluronidase biosimilar has not established the same U.S. market presence as the IV products discussed above.
References
-
U.S. Food and Drug Administration. (2024). Rituxan Hycela prescribing information. Genentech, Inc.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. FDA.
-
Halozyme Therapeutics, Inc. (2024). Form 10-K annual report. U.S. Securities and Exchange Commission.
-
Roche Holding AG. (2022). Annual report 2021. Roche.
-
Roche Holding AG. (2023). Annual report 2022. Roche.
-
Roche Holding AG. (2024). Annual report 2023. Roche.
